Neuroscience of Parkinson's disease

Identify the major structures of the basal ganglia: striatum, globus pallidus, substantia nigra, and subthalamic nucleus.

Trace the flow of information from the cortex through the basal ganglia and back to the cortex via the thalamus.

Describe the 'direct' and 'indirect' pathways of the basal ganglia.

Explain how the balance between the direct and indirect pathways modulates the initiation and execution of voluntary movement.

Analyze a case study showing how basal ganglia damage affects movement control.

Describe the synthesis pathway of dopamine from the amino acid tyrosine.

Identify the major dopaminergic pathways in the brain, focusing on the nigrostriatal and mesolimbic pathways.

Explain the function of D1 and D2 family dopamine receptors in neural signaling.

Describe how dopamine modulates the direct and indirect pathways of the basal ganglia.

Analyze examples of how dopamine levels in the nigrostriatal pathway affect motor function.

Analyze examples of how dopamine levels in the mesolimbic pathway affect motivation and reward.

Describe the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease.

Explain the role of alpha-synuclein protein misfolding and Lewy body formation in neuronal toxicity.

Describe how mitochondrial dysfunction contributes to neuronal death.

Explain the role of oxidative stress in the vulnerability of dopaminergic neurons.

Describe how neuroinflammation can contribute to disease progression.

Analyze microscopy images showing Lewy bodies and neuronal loss in post-mortem Parkinson's brain tissue.

Describe the cardinal motor symptoms of Parkinson's disease: tremor, rigidity, bradykinesia, and postural instability.

Explain how dopamine depletion in the striatum leads to overactivity of the indirect pathway relative to the direct pathway.

Connect the imbalance between the direct and indirect pathways to specific motor symptoms.

Explain why symptoms typically appear only after a substantial loss (60-80%) of dopaminergic neurons.

Analyze video case studies of patients demonstrating different motor symptoms.

Identify common non-motor symptoms of Parkinson's, such as cognitive changes, mood disorders, and sleep disturbances.

Explain how Parkinson's pathology extends to other neurotransmitter systems like serotonin and norepinephrine.

Connect the disruption of non-dopaminergic pathways to symptoms like depression, anxiety, and cognitive deficits.

Describe how pathology in the autonomic nervous system leads to symptoms like orthostatic hypotension and constipation.

Connect olfactory dysfunction (loss of smell) to early-stage pathology in the olfactory bulb.

Analyze case studies illustrating the impact of non-motor symptoms on a patient's quality of life.

Distinguish between sporadic (idiopathic) and familial (genetic) forms of Parkinson's disease.

Identify key genes implicated in familial Parkinson's, including SNCA, LRRK2, Parkin, and PINK1.

Explain how mutations in the SNCA gene can promote the aggregation of alpha-synuclein.

Describe how alpha-synuclein aggregates impair cellular protein disposal systems.

Explain the role of Parkin and PINK1 genes in maintaining mitochondrial health (mitophagy).

Connect mutations in Parkin or PINK1 to the accumulation of dysfunctional mitochondria.

Describe key environmental risk factors associated with Parkinson's, such as pesticide exposure.

Analyze a case study illustrating genetic inheritance patterns in a family with Parkinson's disease.

Explain the rationale for using L-DOPA, a dopamine precursor, as the primary treatment for Parkinson's disease.

Describe why L-DOPA is co-administered with carbidopa to increase its effectiveness in the brain.

Explain how dopamine agonists, MAO-B inhibitors, and COMT inhibitors work to supplement the L-DOPA effect.

Describe the development of motor complications (e.g., dyskinesias) with long-term L-DOPA use.

Compare the benefits and side-effect profiles of different drug classes through patient examples.

Describe the procedure for implanting a deep brain stimulation (DBS) system.

Identify the primary neuroanatomical targets for DBS in Parkinson's and the rationale for their selection.

Explain the proposed mechanisms for how high-frequency stimulation in DBS modulates basal ganglia circuits to alleviate motor symptoms.

Evaluate the criteria used to determine patient candidacy for DBS surgery.

Analyze before-and-after case studies of patients who have received DBS.

Discuss the limitations and potential complications of DBS therapy.

Describe how toxin-based models (e.g., MPTP, 6-OHDA) are used to replicate Parkinson's pathology in animals.

Explain the utility of genetic animal models (e.g., alpha-synuclein overexpressing mice) in studying disease mechanisms.

Identify key experimental techniques used in Parkinson's research, such as immunohistochemistry, behavioral testing, and electrophysiology.

Explain the concept of translational research: bridging discoveries from the lab to clinical practice.

Describe a specific example of a finding from an animal model that successfully translated to human therapy.

Identify the main challenges in translating findings from animal models to human patients.

Describe the concept of neuroprotective therapies aimed at slowing or halting disease progression.

Explain the rationale behind immunotherapy approaches that target the alpha-synuclein protein.

Describe the potential of gene therapy to restore dopamine production or deliver neurotrophic factors.

Explain the principles and challenges of cell replacement strategies, including stem cell therapy.

Analyze the goals and outcomes of a recent clinical trial for an emerging Parkinson's therapy.

Discuss the key challenges in developing and testing disease-modifying therapies for Parkinson's.